4D Mol­e­c­u­lar Ther­a­peu­tics ac­quires eye dis­ease as­set from Fortress Biotech sub­sidiary

Cal­i­for­nia-based biotech 4D Mol­e­c­u­lar Ther­a­peu­tics (4DMT) will be ac­quir­ing the rights to an as­set from a com­pa­ny un­der the Fortress Biotech um­brel­la.

On Mon­day, 4DMT an­nounced it has se­cured rights to the short-form hu­man com­ple­ment fac­tor H (sCFH) as­set from Ae­vi­tas Ther­a­peu­tics, a sub­sidiary of Fortress Biotech. The as­set, in­vent­ed at the Uni­ver­si­ty of Penn­syl­va­nia, is a form of a nat­ur­al in­hibitor of the in­flam­ma­to­ry com­ple­ment path­way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER